Standard Chartered GBS donates INR 3.4 Cr to support fight against COVID-19
· Funds to be utilised to develop testing reagents, provide protective sets, test kits, meals and essentials to vulnerable groups
Standard Chartered Global Business Services Pvt Ltd (GBS) has donated INR 3.4 crores to support the fight against COVID-19 virus in India. Driven by the organisational values #DoTheRightThing and #BetterTogether, GBS has tied up with multiple non-government organisation (NGO) partners, to support the country in its fight against the deadly virus.
GBS has extended its support to the National Centre for Biological Sciences (NCBS), a unit of Tata Institute of Fundamental Research (NCBS-TIFR) to develop local reagents, a solution that is used during the RNA testing to detect the virus. GBS has also funded NCBS to support the testing of 2,800 underprivileged people. With United Way, Bengaluru, GBS is funding 2000 protective kits comprising of three-layer masks, disposable shoe covers, surgical gloves etc., and 2000 COVID-19 Test kits that will be handed over to Government Hospitals. GBS has also donated 25,000 face masks to Concern India, who in turn will be handing over these masks to the government hospitals and health workers.
In addition, GBS has partnered with Akshaya Patra in Bengaluru, who will provide all meals for 15,000 people during the 45 days lockdown period. These are migrants, daily wage workers, construction workers, and contract labourers. Apart from the above, GBS has also announced to support all meals and sanitary requirements of the 200 occupants of the Sevalaya old age home and orphanage in Chennai.
As the COVID-19 crisis evolves, the need of the hour is for all of us to come together to counter the threat of this virus that has seen a global outbreak.
Matthew Norris, CEO Standard Chartered Global Business Services said, “These are challenging times, globally and we are doing whatever we can, to help ease the stress for some of the most needy in our communities and support the fight against the COVID-19 pandemic”.